Within the last 3 years a prospective study on 70 pregnant women suffering from hypotension was carried out. In all these patients the endocrine placental function was examined regularly by measuring the HPL and E3 level in the maternal serum (from the 16th week of pregnancy onwards). In order to get information on the uteroplacental perfusion rate, placental flow measurements using radioisotopes were carried out. Whereas the endocrine parameters revealed no abnormality, the results of the flow measurements were significantly low in more than 80%. In 30 out of the total of 70 patients no medication was given and after termination of pregnancy the fetal outcome was investigated. The neonates of this group were significantly smaller than normal, the rate of dystrophy was considerably high. The other 40 women were subjected to a drug regimen. Depending on pressure values and type of complaints they were given a crystal suspension of deoxycorticosterone trimethylacetate intramuscularly. In this group of patients the placental perfusion rate improved significantly after medication, the fetal outcome did not differ in comparison to cases with normotension. In the light of our study we suggest that a maternal blood pressure of 110/65 and below has to be treated not only because of maternal indication, but as well because of the fetus’ sake.

Keywords:
Hypotension, Pregnancy, Placental perfusion, Prematurity, Prenatal dystrophy, Mineralocorticoid treatment
This content is only available via PDF.
© 1979 S. Karger AG, Basel
1979
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.